CLINUVEL share price races higher following Q2 update

The CLINUVEL Pharmaceuticals Limited (ASX:CUV) share price is charging higher following the release of its second quarter update…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price has been a strong performer on Friday.

In morning trade the biopharmaceutical company's shares are up 4% to $28.09.

Why is the CLINUVEL share price racing higher?

Investors have been buying the company's shares following the release of its second quarter update.

According to the release, receipts from customers were ~$3.7 million for the quarter ending December 31. This was a 43% increase on the prior corresponding period. This brought its financial year to date receipts from customers to $13.5 million.

CLINUVEL's cash and cash equivalents at the end of the period was $57.4 million. This was a reduction of $0.9 million from the previous quarter.

Management advised that the movement in cash was largely driven by net cash used in operating activities of $0.6 million. Which was due to management preparing to expand into new markets in 2020 and beyond. This follows FDA approval for its SCENESSE product late last year.

In addition to this, as its SCENESSE product is for erythropoietic protoporphyria (EPP), a rare genetic disorder which causes absolute intolerance of skin to sunlight, unit orders are traditionally lower during the northern hemisphere's winter months compared to spring and summer.

CLINUVEL's Chief Financial Officer, Darren Keamy, was pleased with the quarter.

He said: "We are starting to witness an annual trend in our sales receipts through the European winter months, while we expect to receive more orders as spring and summer approaches."

"Following FDA approval, we are fully committed to our growth plans in the US and to progress our product pipeline. This commitment will be balanced with the careful and deliberate cashflow management that CLINUVEL has demonstrated over years of research and development and commercial operations. This will be a primary focus in 2020," Mr Keamy added.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Man sitting in a plane looking through a window and working on a laptop.
Broker Notes

Should you buy Qantas shares before reporting season? Here's what Macquarie recommends

We look at Macquarie’s expectations for the surging Qantas share price in FY 2026.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »

A set of scales with a bag of money balanced against a timer, indicating growth versus value shares
Opinions

Which ASX sector offers the best value heading into earnings season?

I think one sector is particularly compelling.

Read more »

Green stock market graph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was one for the history books today.

Read more »

Person holding a blue chip.
Blue Chip Shares

4 ASX 200 blue-chip shares to hold but not buy: experts

These blue-chips are worth holding if you already own them, but are too expensive for new investors to buy.

Read more »

A bricklayer peeps over the top of a brick wall he is laying with a level measuring tool on top.
Broker Notes

Are Brickworks shares a buy, hold or sell ahead of earnings season?

Brokers have been weighing property gains, US headwinds, and merger impacts to form a view.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Green stock market graph with a rising arrow symbolising a rising share price.
Record Highs

The ASX 200 just hit a new record high. Here's why.

The prospect of lower interest rates is pushing the market into new territory.

Read more »